Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06126913

HeadStART: Evaluating the Effectiveness of Community ART Delivery for People Newly Diagnosed With HIV

This is a cluster randomized controlled trial at 12 health centers in refugee settlements in Uganda aiming to evaluate effectiveness of expansion of community antiretroviral therapy (ART) delivery to people newly diagnosed with HIV in achieving HIV viral suppression.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Infectious Diseases Institute, Makerere University

Kampala, Uganda

Location status: Recruiting

Location contact

Timothy Muwonge

CONTACT

About this study

Community antiretroviral therapy (ART) delivery is a differentiated care model that fosters social support and reduces time and transportation barriers yielding improved engagement in HIV care. In Uganda, to participate in community ART delivery, clients must be "stable" in care (> 1 year on ART and viral load < 1,000 copies/mL). Therefore, persons newly diagnosed with HIV are not eligible for community ART delivery. Community ART delivery may benefit persons newly diagnosed with HIV in refugee settlements by bolstering social support and by bringing ART closer to individuals living in these expansive rural settlements. The primary objective of this research is to evaluate the effectiveness of expanding community ART delivery to clients newly diagnosed with HIV.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Adult ≥18 years of age or mature minors or emancipated minor. Mature minors are defined as individuals 14-17 years of age who have drug or alcohol dependency or a sexually transmitted infection. Emancipated minors are defined as individuals below the age of majority (18 years) who are pregnant, married, have a child, or are self-sufficient.
  • Tested HIV positive in the past 6 months and not already known to be HIV positive.
  • Able to communicate in one of the following 5 study languages: Kiswahili, Runyankore, Kinyarwanda, Somali, or English.

Inclusion criteria

for data abstraction only:

  • Adult ≥18 years of age or mature minors or emancipated minor.
  • Tested HIV positive in the past 6 months and not already known to be HIV positive.

Exclusion criteria

  • Pregnant and breastfeeding women.
  • Clients deemed by the clinician(s) unfit for community-based care secondary to medical need.
  • Concurrently enrolled in another biomedical clinical trial.

Treatment and study plan

Community Antiretroviral Therapy

Other

Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.

Primary outcomes

  1. HIV viral suppression at 12 months

    Time frame: 12 months (+/- 2 months)

    HIV viral suppression is defined as <1,000 copies/mL

Secondary outcomes

  1. HIV viral suppression at 6 months

    Time frame: 6 months (+/- 2 months)

    HIV viral suppression is defined as <1,000 copies/mL

  2. Antiretroviral therapy adherence among those virally unsuppressed at 12 months

    Time frame: 12 months (+/- 2 months)

    assessed by determining tenofovir diphosphate blood concentrations among those virally unsuppressed

Study contacts

Contact information is provided by the study sponsor or research team.

Kelli O'Laughlin, MD, MPH

CONTACT

[email protected]

Layla Anderson

CONTACT

[email protected]

206-744-5594

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Official study title

Achieving HIV Viral Suppression in Refugee Settlements in Uganda With Head StART: A Cluster Randomized Trial Evaluating the Effectiveness of Community ART Delivery for People Newly Diagnosed With HIV

Acronym: HeadStART

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Nov 13, 2023
Registry last updated
Jan 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.